Precision BioSciences (NASDAQ:DTIL) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Precision BioSciences (NASDAQ:DTIL) in a report issued on Wednesday,Benzinga reports. They currently have a $60.00 price objective on the stock.

Separately, BMO Capital Markets raised Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price target for the company in a research note on Friday, January 10th.

Precision BioSciences Trading Up 0.6 %

Shares of NASDAQ DTIL opened at $5.01 on Wednesday. The stock has a market cap of $38.43 million, a price-to-earnings ratio of 83.51 and a beta of 1.59. The business has a 50 day simple moving average of $5.13 and a 200 day simple moving average of $6.78. Precision BioSciences has a 52 week low of $3.61 and a 52 week high of $15.97. The company has a debt-to-equity ratio of 0.34, a quick ratio of 9.22 and a current ratio of 9.22.

Insider Buying and Selling

In related news, CEO Michael Amoroso sold 36,838 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $4.67, for a total value of $172,033.46. Following the completion of the sale, the chief executive officer now directly owns 107,087 shares in the company, valued at approximately $500,096.29. The trade was a 25.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider J. Jefferson Smith sold 10,287 shares of the business’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $4.79, for a total value of $49,274.73. Following the completion of the sale, the insider now owns 87,440 shares of the company’s stock, valued at approximately $418,837.60. This trade represents a 10.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders purchased 8,734 shares of company stock worth $39,946 and sold 47,279 shares worth $222,064. Corporate insiders own 4.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of DTIL. Janus Henderson Group PLC lifted its holdings in shares of Precision BioSciences by 10.9% during the third quarter. Janus Henderson Group PLC now owns 702,069 shares of the company’s stock worth $6,322,000 after buying an additional 68,943 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Precision BioSciences by 40.7% during the third quarter. Geode Capital Management LLC now owns 65,974 shares of the company’s stock worth $591,000 after buying an additional 19,088 shares during the last quarter. Moloney Securities Asset Management LLC lifted its holdings in shares of Precision BioSciences by 177.0% during the fourth quarter. Moloney Securities Asset Management LLC now owns 87,799 shares of the company’s stock worth $335,000 after buying an additional 56,100 shares during the last quarter. Commonwealth Equity Services LLC acquired a new position in shares of Precision BioSciences during the fourth quarter worth approximately $48,000. Finally, Samalin Investment Counsel LLC acquired a new position in shares of Precision BioSciences during the fourth quarter worth approximately $59,000. 37.99% of the stock is currently owned by institutional investors and hedge funds.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.